The Relationship Between Clinicopathological Features and Prognosis of 22 Cases of Tubular Breast Carcinoma

IF 1.9 4区医学 Q3 OBSTETRICS & GYNECOLOGY

Breast Journal Pub Date : 2025-02-03 DOI:10.1155/tbj/5599018

Lin Tian, Xiangchao Meng, Huiyan Si, Yue Qiu, Rui Qu, Hongye Chen

{"title":"The Relationship Between Clinicopathological Features and Prognosis of 22 Cases of Tubular Breast Carcinoma","authors":"Lin Tian, Xiangchao Meng, Huiyan Si, Yue Qiu, Rui Qu, Hongye Chen","doi":"10.1155/tbj/5599018","DOIUrl":null,"url":null,"abstract":"<div>\n Background: Breast tubular carcinoma is a special pathological type of invasive breast cancer, accounting for about 0.8% to 10.0% of breast cancer cases, and it is a rare type of breast cancer. Currently, there is still a lack of relevant diagnostic and treatment consensus. Exploring the relationship between the pathological characteristics, molecular subtypes, and prognosis of ductal breast cancer is of great scientific value and clinical significance for improving patients’ survival rate and quality of life.\n Methods: The clinical data of 22 patients with tubular breast carcinoma diagnosed by pathology in The First Medical Center of PLA General Hospital from January 2001 to December 2021 were collected, and their pathological features, molecular classification, and prognosis were analyzed retrospectively.\n Results: The clinicopathological features of 22 patients with tubular breast carcinoma were age ≥ 35 years, married, tumor ≤ 2 cm, single focal, mixed type, no lymph node metastasis, estrogen receptor (ER) positive, progesterone receptor (PR) positive, Ki-67 ≤ 14%, CyclinD1 negative, less recurrence, and metastasis. Twenty-two patients with breast tubular carcinoma were followed up for 5 years after surgery, and the survival rate of disease-free survival (DFS) was 90.9% (20/22). The positive rates of ER, PR, and human epidermal growth factor receptor-2 (HER-2) are 100.0%, 100.0%, and 40.9%, respectively. The proportion of tumor cells expressing Ki-67 is 45.4%. Among them, the difference of HER-2 level, recurrence and metastasis, and postoperative comprehensive treatment showed different prognoses.\n Conclusion: Tubular breast carcinoma is a kind of tumor with a low malignant degree. The prognosis is significantly related to its HER-2 level, recurrence and metastasis, and postoperative comprehensive treatment by univariate analysis, in which HER-2 is an independent risk factor, postoperative comprehensive treatment is a protective factor, but postoperative recurrence and metastasis have nothing to do with the prognosis by the multivariate analysis.\n </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2025 1","pages":""},"PeriodicalIF":1.9000,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/tbj/5599018","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast Journal","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/tbj/5599018","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast tubular carcinoma is a special pathological type of invasive breast cancer, accounting for about 0.8% to 10.0% of breast cancer cases, and it is a rare type of breast cancer. Currently, there is still a lack of relevant diagnostic and treatment consensus. Exploring the relationship between the pathological characteristics, molecular subtypes, and prognosis of ductal breast cancer is of great scientific value and clinical significance for improving patients’ survival rate and quality of life.

Methods: The clinical data of 22 patients with tubular breast carcinoma diagnosed by pathology in The First Medical Center of PLA General Hospital from January 2001 to December 2021 were collected, and their pathological features, molecular classification, and prognosis were analyzed retrospectively.

Results: The clinicopathological features of 22 patients with tubular breast carcinoma were age ≥ 35 years, married, tumor ≤ 2 cm, single focal, mixed type, no lymph node metastasis, estrogen receptor (ER) positive, progesterone receptor (PR) positive, Ki-67 ≤ 14%, CyclinD1 negative, less recurrence, and metastasis. Twenty-two patients with breast tubular carcinoma were followed up for 5 years after surgery, and the survival rate of disease-free survival (DFS) was 90.9% (20/22). The positive rates of ER, PR, and human epidermal growth factor receptor-2 (HER-2) are 100.0%, 100.0%, and 40.9%, respectively. The proportion of tumor cells expressing Ki-67 is 45.4%. Among them, the difference of HER-2 level, recurrence and metastasis, and postoperative comprehensive treatment showed different prognoses.

Conclusion: Tubular breast carcinoma is a kind of tumor with a low malignant degree. The prognosis is significantly related to its HER-2 level, recurrence and metastasis, and postoperative comprehensive treatment by univariate analysis, in which HER-2 is an independent risk factor, postoperative comprehensive treatment is a protective factor, but postoperative recurrence and metastasis have nothing to do with the prognosis by the multivariate analysis.

Abstract Image

查看原文本刊更多论文

22例管状乳腺癌临床病理特征与预后的关系

背景：乳腺小管癌是浸润性乳腺癌中一种特殊的病理类型，约占乳腺癌病例的0.8% ~ 10.0%，是一种罕见的乳腺癌类型。目前，仍缺乏相关的诊断和治疗共识。探讨导管性乳腺癌的病理特征、分子亚型与预后的关系，对提高患者的生存率和生活质量具有重要的科学价值和临床意义。方法：收集2001年1月至2021年12月解放军总医院第一医学中心经病理诊断的22例小管性乳腺癌患者的临床资料，回顾性分析其病理特征、分子分型及预后。结果：22例小管性乳腺癌患者的临床病理特征为：年龄≥35岁，已婚，肿瘤≤2 cm，单灶，混合型，无淋巴结转移，雌激素受体（ER）阳性，孕激素受体（PR）阳性，Ki-67≤14%，CyclinD1阴性，复发及转移少。22例乳小管癌患者术后随访5年，无病生存率（DFS）为90.9%（20/22）。ER、PR和人表皮生长因子受体-2 （HER-2）阳性率分别为100.0%、100.0%和40.9%。表达Ki-67的肿瘤细胞比例为45.4%。其中HER-2水平、复发转移及术后综合治疗的差异表现出不同的预后。结论：管状乳腺癌是一种恶性程度较低的肿瘤。单因素分析其预后与其HER-2水平、复发转移及术后综合治疗显著相关，其中HER-2为独立危险因素，术后综合治疗为保护因素，但多因素分析其术后复发转移与预后无关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Journal 医学-妇产科学

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： The Breast Journal is the first comprehensive, multidisciplinary source devoted exclusively to all facets of research, diagnosis, and treatment of breast disease. The Breast Journal encompasses the latest news and technologies from the many medical specialties concerned with breast disease care in order to address the disease within the context of an integrated breast health care. This editorial philosophy recognizes the special social, sexual, and psychological considerations that distinguish cancer, and breast cancer in particular, from other serious diseases. Topics specifically within the scope of The Breast Journal include: Risk Factors Prevention Early Detection Diagnosis and Therapy Psychological Issues Quality of Life Biology of Breast Cancer.